NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Crispr Therapeutics AG CRSP
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.5M
▼ 90.6% vs FY2024
EPS · FY25
$-6.47
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-30.2%
Net margin · FY25
-16569.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.5M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 16570 cents on every revenue dollar this year.
Per share
USD -6.47
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-30.2%
Return on equity, FY2025
ROE
Operating margin-18933.6%
Net margin-16569.8%
Return on assets-25.8%
Each USD of equity lost 30 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+37.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+43.1%
+37.3%
+30.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+29.7%
Change, 10 years—
The share count grew 30% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.3B
total assets, end of FY2025
Total assetsUSD 2.3B
EquityUSD 1.9B
CashUSD 347.6M
Current ratio13.32×
Equity funds 85% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.4
0.0
0.9
0.0
0.3
0.0
0.0
0.0
0.0
·
Operating income $B
−0.7
−0.5
−0.2
−0.7
0.4
−0.4
0.0
−0.2
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.6
−0.4
−0.2
−0.6
0.4
−0.3
0.1
−0.2
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.6
−0.4
−0.2
−0.7
0.4
−0.3
0.1
−0.2
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−6.47
−4.34
−1.94
−8.36
4.70
−5.29
1.17
−3.44
−1.71
−1.89
−5.06
1.97
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−30.2
−19.2
−8.2
−30.4
18.6
−26.8
10.0
−56.9
−32.5
−22.8
·
·
Shares out B
0.10
0.09
0.08
0.08
0.08
0.07
0.06
0.05
0.04
0.04
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed